Clinical trials: Helicobacter
Helicobacter Pylori Infection
The Status of Helicobacter Pylori Infection Among Children Visiting Assiut Children Hospital
The aim of this study is to estimate the prevalence of Helicobacter pylori infection among Egyptian children attending to healthcare facilitates using different diagnostic tools.
- Trial name
- NCT04212585
- Testing
- Serology test
- Volunteers
- 100 people
- Sponsor
- Assiut University
Helicobacter Pylori Infection Chronic Gastrit
Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment
The purpose of this study was to evaluate the efficacy and safety of tegoprazan and minocycline dual therapy for Helicobacter pylori initial treatment.
- Trial name
- NCT06523764
- Testing
- tegoprazan, Minocycline, bismuth potassium citrate
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Helicobacter Pylori Infection
Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy
Reverse hybrid therapy achieves a higher eradication rate than concomitant therapy remains unanswered.
- Trial name
- NCT02646332
- Testing
- (dexlan+amox+clar+metr)+(dexlan+amox), dexlan+clarith+amox+metro
- Where
- Taiwan
- Volunteers
- 248 people
- Sponsor
- Kaohsiung Veterans General Hospital.
H Pylori Infection
Helicobacter Pylori and it's Hematological Impact
To evaluate the effect of helicobacter pylori on the blood for proper management
- Trial name
- NCT03629587
- Volunteers
- 100 people
- Sponsor
- Assiut University
Helicobacter Pylori Infection
Eradication of Helicobacter Pylori With a Lactobacillus Reuteri Strain Plus Proton Pump Inhibitor
Meta-analyses involving >4000 subjects with probiotics added to antimicrobial Helicobacter pylori eradication therapy in populations with antibiotic resistance have reported a mean increase in eradication rate of 12.2%.
- Trial name
- NCT03404440
- Testing
- L.Reuteri
- Where
- Italy
- Volunteers
- 56 people
- Sponsor
- University of Bari
Eradication Rates of the Two Regimens
Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy
The investigators aimed to compare the eradication rates of sequential therapy for 10 days versus triple therapy for 14 days
- Trial name
- THC (NCT01607918)
- Testing
- D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole), D1-D14: (lansoprazole + clarithromycin + amoxicillin)
- Where
- Taiwan
- Volunteers
- 1,300 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection, Intestinal Bacteria Flora Disturbance
Fucoidan Assisted Eradication of Helicobacter Pylori
The purpose of this study is to investigate whether the eradication rate of H.pylori will be improved when adding fucoidan to the duplex scheme combination of amoxicillin and vonoprazan, and to explore the effect of fucoidan on…
- Trial name
- NCT05461508
- Testing
- Amoxicillin combined with vonoprazan and fucoidan, Amoxicillin combined with vonoprazan
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Helicobacter Pylori Infection
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days
The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy.
- Trial name
- NCT04901117
- Testing
- Amoxicillin, Clarithromycin, Tetracycline
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Shandong University
Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing
Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment
Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer.
- Trial name
- NCT02988089
- Testing
- Clarithromycin susceptibility dependant strategy, 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline ), proton pump inhibitor (PPI) and Colloidal Bismuth Pectin
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shandong University
Helicobacter Pylori
Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management
The study will evaluate the eradication rate and tolerability of modified LOAD regimens (three antibiotics and a proton pump inhibitor (lansoprazole)) for management of HP infection in treatment-naive patients as well as patients…
- Trial name
- NILE (NCT05184491)
- Testing
- Naïve patients - ACO therapy, Naïve patients - LNDL therapy, Naïve patients - MNDL therapy
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- National Liver Institute, Egypt
H.Pylori Infection
Barriers of General Practitioner Regarding Helicobacter Pylori.
This study aims to evaluate the knowledge, attitudes, and clinical practices of general practitioners regarding the diagnosis and treatment of Helicobacter pylori infection.
- Trial name
- NCT07284355
- Volunteers
- 300 people
- Sponsor
- Assiut University
Helicobacter Infections, Bacterial Infections
Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.
The purpose of the study is to confirm the safety and effectiveness of rabeprazole in the treatment of adult patients with Helicobacter pylori (H. pylori) infection in routine clinical practice.
- Trial name
- NCT00216450
- Testing
- rabeprazole sodium
- Volunteers
- 80 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Peptic Ulcer
The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients
This study assessed the effect of tailored eradication therapy according to Clarithromycin resistance in Helicobacter pylori patients.
- Trial name
- NCT02648659
- Testing
- Ilaprazole, Amoxicillin, Clarithromycin
- Volunteers
- 50 people
- Sponsor
- Kyungpook National University Hospital
Helicobacter Pylori, Drug Resistance, Multiple
Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains
The goal of this clinical trial is to learn if the 14-day susceptibility-guided bismuth quadruple therapy works to treat multiple drug resistant Helicobacter pylori (H. pylori) in adults.
- Conditions
- Helicobacter Pylori, Drug Resistance, Multiple, Virulence Factor
- Trial name
- BSUS-1 (NCT06687473)
- Testing
- Bismuth-based susceptibility-guided treatment
- Where
- Taiwan
- Volunteers
- 13 people
- Sponsor
- National Cheng-Kung University Hospital
Helicobacter Pylori Infection, Gastritis
NLR and PLR in H. Pylori-Associated Gastritis
This cross-sectional study aims to evaluate the role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as inflammatory markers in patients with Helicobacter pylori-associated gastritis at Assiut…
- Conditions
- Helicobacter Pylori Infection, Gastritis, Dyspepsia
- Trial name
- NCT07805005
- Volunteers
- 90 people
- Sponsor
- Assiut University
Pulmonary Disease, Oropharyngeal Disease
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
This study will examine bacteria and toxins in the mouth, lung and digestive system that may be the cause of various diseases or symptoms. H.
- Conditions
- Pulmonary Disease, Oropharyngeal Disease, Lymphangioleiomyomatosis, Pulmonary Fibrosis
- Trial name
- NCT00366509
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
H.Pylori Infection
Tegoprazan- Versus PPI-based H. Pylori Eradication
In 2015, vonoprazan, a potassium-competitive blocker (P-CAB), was launched in Japan and used as an alternative for proton pump inhibitors (PPIs) for eradicating Helicobacter pylori.
- Trial name
- NCT06682533
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Soonchunhyang University Hospital
H.Pylori Infection
Relation of Helicobacter Pylori in Prediabetic Patients
The primary objective of this study is to : find the relation between H.pylori infection and pre-diabetic patients with lipid profile . Specifically, the study aims to: 1. affect of H.pylori infection in pre-diabetic patients 2.
- Trial name
- NCT06176547
- Testing
- HbA1c
- Volunteers
- 82 people
- Sponsor
- Assiut University
Helicobacter Pylori Infection
High Dose of Dual Therapy Plus Bismuth for Helicobacter Pylori Treatment
Dual therapy for Helicobacter Pylori including a proton pump inhibitor (PPI) and amoxicillin. Amoxicillin has low resistance rate as well as low percentage of side effects.
- Trial name
- NCT03405584
- Testing
- Esomeprazole, Amoxicillin, Bismuth Potassium Citrate
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Helicobacter Infections, Gastritis
Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori
The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and…
- Conditions
- Helicobacter Infections, Gastritis, Gastric Ulcer, Duodenal Ulcer
- Trial name
- NCT00149084
- Testing
- Lansoprazole, clarithromycin, amoxicillin
- Where
- Japan
- Volunteers
- 296 people
- Sponsor
- Hamamatsu University